The estimated Net Worth of Kaye I Foster Cheek is at least $1.66 Million dollars as of 13 June 2024. Kaye Cheek owns over 3,388 units of Johnson & Johnson stock worth over $1,468,876 and over the last 20 years Kaye sold JNJ stock worth over $191,512.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Kaye Cheek JNJ stock SEC Form 4 insiders trading
Kaye has made over 11 trades of the Johnson & Johnson stock since 2018, according to the Form 4 filled with the SEC. Most recently Kaye exercised 3,388 units of JNJ stock worth $558,410 on 13 June 2024.
The largest trade Kaye's ever made was exercising 25,000 units of Johnson & Johnson stock on 9 August 2023 worth over $452,250. On average, Kaye trades about 1,276 units every 47 days since 2005. As of 13 June 2024 Kaye still owns at least 8,912 units of Johnson & Johnson stock.
You can see the complete history of Kaye Cheek stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kaye Cheek's mailing address?
Kaye's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Johnson & Johnson
Over the last 22 years, insiders at Johnson & Johnson have traded over $59,929,946 worth of Johnson & Johnson stock and bought 21,998 units worth $2,578,685 . The most active insiders traders include Hubert Joly, Anne M Mulcahy, and Alex Gorsky. On average, Johnson & Johnson executives and independent directors trade stock every 21 days with the average trade being worth of $4,572,436. The most recent stock trade was executed by Robert J Decker on 30 August 2024, trading 5,635 units of JNJ stock currently worth $563,838.
What does Johnson & Johnson do?
Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
What does Johnson & Johnson's logo look like?
Complete history of Kaye Cheek stock trades at Agios Pharmaceuticals Inc and Johnson & Johnson
Johnson & Johnson executives and stock owners
Johnson & Johnson executives and other stock owners filed with the SEC include:
-
Alex Gorsky,
Chairman of the Board, Chief Executive Officer -
Paulus Stoffels,
Vice Chairman- Executive Committee, Chief Scientific Officer -
Joaquin Duato,
Vice Chairman - Executive Committee -
Joseph Wolk,
Chief Financial Officer, Executive Vice President -
Jennifer Taubert,
Executive Vice President - Worldwide Chairman, Pharmaceuticals -
Michael Ullmann,
Executive Vice President, General Counsel -
Alex Gorsky,
Exec. Chairman -
Peter Fasolo,
Chief Human Resource Officer, Executive Vice President -
Dr. Paulus A. Stoffels M.D., Ph.D.,
Chief Scientific Officer -
Joaquin Duato,
CEO & Director -
Joseph J. Wolk CPA,
Exec. VP & CFO -
Joseph J. Wolk C.P.A.,
Exec. VP & CFO -
Jennifer L. Taubert,
Exec. VP & Worldwide Chairman of Pharmaceuticals -
Anne Mulcahy,
Lead Independent Director -
Charles Prince,
Independent Director -
Mary Beckerle,
Independent Director -
Ronald Williams,
Independent Director -
D. Scott Davis,
Independent Director -
A. Eugene Washington,
Independent Director -
Jennifer Doudna,
Independent Director -
Mark McClellan,
Independent Director -
Ian Davis,
Independent Director -
Marillyn Hewson,
Independent Director -
Mark Weinberger,
Independent Director -
Hubert Joly,
Independent Director -
Christopher DelOrefice,
Vice President, Investor Relations -
Kathryn Wengel,
Executive Vice President, Chief Global Supply Chain Officer -
Michael Sneed,
Executive Vice President - Global Corporate Affairs and Chief Communication Officer -
Thibaut Mongon,
Executive Vice President, Worldwide Chairman, Consumer -
Ashley McEvoy,
Executive Vice President - Worldwide Chairman, Medical Devices -
Dr. Guy J. Lebeau M.D.,
Group Chairman of MD&D Bus. - EMEA -
Dr. Peter M. Fasolo Ph.D.,
Exec. VP & Chief HR Officer -
Michael H. Ullmann,
Exec. VP & Gen. Counsel -
Jessica Moore,
VP of Investor Relations -
Ashley Watson,
Chief Compliance Officer -
James Swanson,
Exec. VP & Global CIO -
Robert J. Decker Jr.,
Controller & Chief Accounting Officer -
James Cullen,
Director -
Stephen J Cosgrove,
-
Leo F Mullin,
Director -
Michael M E Johns,
Director -
Robert J Decker,
VP Corporate Controller -
Elizabeth Forminard,
Executive VP, General Counsel -
Ronald A Kapusta,
Controller, CAO -
Susan L Lindquist,
Director -
Gary J Pruden,
Exec VP, WW Chair, Med Devices -
William D Perez,
Director -
Jorge S. Mesquita,
Exec VP, WW Chair, Consumer -
Dominic J Caruso,
Chief Financial Officer -
Timothy Schmid,
EVP, WW Chair, MedTech -
Mary Sue Coleman,
Director -
David Satcher,
Director -
William C Weldon,
Chairman/CEO -
Arnold G Langbo,
Director -
Russell C Deyo,
Vice President, Administration -
Kaye I Foster Cheek,
VP, Human Resources -
Colleen A Goggins,
Member, Executive Committee -
Sherilyn S Mc Coy,
Member, Executive Committee -
Donald M Jr. Casey,
Member, Executive Committee -
Nicholas J Valeriani,
Vice President,Human Resources -
Christine A Poon,
Executive Committee Member -
Joseph C Scodari,
Executive Committee Member -
Steven Reinemund,
Director -
Ann Dibble Jordan,
Director -
Robert J Darretta,
Member, Executive Committee -
Per A Peterson,
Executive Committee Member -
Michael J Dormer,
Member, Executive Committee -
Joann Heffernan Heisen,
Member, Executive Committee -
Gerard N Burrow,
Director -
Henry B Schacht,
Director -
M Judah Folkman,
Director -
Roger S Fine,
Vice President General Counsel -
James T Lenehan,
Vice Chairman -
Brian D Perkins,
Executive Committee Member -
Robert N Wilson,
-
Nadja West,
Director -
Vanessa Broadhurst,
EVP, Global Corp Affairs -
Mathai Mammen,
EVP, Pharm, R&D -
William Hait,
EVP, Chief EI and Med Officer -
Darius Adamczyk,
Director -
James D. Swanson,
EVP, CIO -
John C Reed,
EVP, Innovative Medicine, R&D -
Paula A Johnson,
Director -
Eugene A. Woods,
Director